This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Boston Scientific (BSX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Insulet (PODD) closed at $286.13, marking a -1.23% move from the previous day.
Insulet (PODD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $289.70, moving -0.68% from the previous trading session.
Insulet (PODD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed at $292.38 in the latest trading session, marking a +1.11% move from the prior day.
Insulet (PODD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $305.89, moving -0.13% from the previous trading session.
Insulet (PODD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Insulet (PODD) closed the most recent trading day at $296.27, moving +1.35% from the previous trading session.
Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise
by Zacks Equity Research
Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.
Is Nuveen ESG MidCap Growth ETF (NUMG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NUMG
Insulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 7th
by Zacks Equity Research
GIII, PODD and LU have been added to the Zacks Rank #5 (Strong Sell) List on October 7, 2022.
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
Insulet (PODD) to Expand Base in Malaysia With New Facility
by Zacks Equity Research
The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.
Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.
Insulet (PODD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
by Debanjana Dey
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
Refresh Your Portfolio by Dumping These 5 Toxic Stocks
by Rimmi Singhi
Get rid of toxic stocks like GoodRx (GDRX), Insulet (PODD), Vonage (VG), AppLovin (APP) and Embraer (ERJ) to avoid portfolio bleeding.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.
Insulet (PODD) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.